#SITC26: Immunocore reports early data for brenetafusp plus Kimmtrak in uveal melanoma
In an early test of two bispecific T cell engagers combined in a solid tumor, Immunocore said an estimated 70% of certain uveal melanoma patients were alive at two years after receiving the doublet in ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.